PGLYRP2 and COVID-19: Most of the chosen markers change in abundance between healthy and COVID-19-infected individuals, and further follow their respective trend with increasing treatment escalation level, such as peptides derived from the acute-phase proteins CRP and AHSG, or the innate-immune-response protein PGLYRP2 (Figure 3a, Figure 3b).